Re-Engineered Discharge for Diabetes Care Transitions
Official title: Re-Engineered Discharge for Diabetes Care Transitions: Screening and Addressing Social Determinants of Health Needs at Hospital Discharge
Run by University of Massachusetts, Worcester · NCT06869057 · Data updated 2026-11-12
A computer-based screening for social needs and a post-discharge navigator are being tested to help adults with type 2 diabetes after hospitalization see if addressing unmet social needs reduces readmission.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 412 (estimated) |
| Sponsor | University of Massachusetts, Worcester Academic / other |
| Locations | 1 site (Worcester, Massachusetts) |
| Status | Recruiting |
| Started | June 8, 2026 |
| Main results expected | December 1, 2028 |
| Study ends | May 30, 2029 |
| Registry record updated | June 30, 2026 |
| Trial ID | NCT06869057 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with type 2 diabetes who are hospitalized and report at least one unmet social need.
✕Probably not a fit
Patients without unmet social needs or those unable to participate in post-discharge navigation may see no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study tests a bedside social determinants of health (SDOH) screening tool combined with a care-coordination protocol after discharge for adults with type 2 diabetes. Participants are randomized to receive either a post-discharge navigation service or usual care, with follow-up surveys at 0, 30, and 90 days. A patient navigator helps address identified social needs during the 90 days after hospital discharge, while the control group receives standard resources. Data collection includes self-reported surveys and medical record abstraction to assess impact on readmission-related outcomes and social needs. The trial is conducted at UMASS Memorial Healthcare System with collaboration from NINR and the University of Michigan.
Why it matters
Potential benefit: If successful, the approach could reduce hospital readmissions by addressing patients' social barriers to diabetes self-management.
How similar studies have gone: Previous work in SDOD- or navigator-led post-discharge programs has shown potential to improve care coordination and reduce readmissions in some populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult aged 18 years or older * diagnosed with type 2 diabetes * hospitalized at Univ of Massachusetts-affiliated hospital * endorsed at least 1 unmet social need via screening survey Exclusion Criteria: * pregnancy * discharge to short or long-term nursing facility or hospital * medical contraindication * cognitive impairment * unable to provide informed consent
Where it's running
-
UMASS Memorial Healthcare System
Worcester, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: Suzanne Mitchell, MD, MS
- Email: Suzanne.Mitchell2@umassmed.edu
- Phone: 774-441-6225
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin
This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.